Split History
ETFs Holding INFI »    INFI Historical Stock Prices »
Video: What is a Stock Split?

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Infinity Pharmaceuticals is a clinical-stage biopharmaceutical company. Co. is focused on advancing eganelisib (IPI-549), an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma. The preclinical findings indicate that eganelisib may have the potential to treat various solid tumors and represents an additive or synergistic approach to restoring anti-tumor immunity in combination with other immunotherapies such as checkpoint inhibitors. Further, preclinical studies showed that eganelisib inhibits the regrowth of tumors that can occur following treatment with chemotherapy. According to our INFI split history records, Infinity Pharmaceuticals has had 1 split.
INFI split history picture
Infinity Pharmaceuticals (INFI) has 1 split in our INFI split history database. The split for INFI took place on September 13, 2006. This was a 1 for 4 reverse split, meaning for each 4 shares of INFI owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 250 share position following the split.

When a company such as Infinity Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the INFI split history from start to finish, an original position size of 1000 shares would have turned into 250 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Infinity Pharmaceuticals shares, starting with a $10,000 purchase of INFI, presented on a split-history-adjusted basis factoring in the complete INFI split history. INFI split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 02/01/2013
End date: 01/30/2023
Start price/share: $34.12
End price/share: $0.61
Dividends collected/share: $0.00
Total return: -98.21%
Average Annual Total Return: -33.13%
Starting investment: $10,000.00
Ending investment: $178.78
Years: 10.00
Date Ratio
09/13/20061 for 4
INFI is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

INKT Split History
INNT Split History
INO Split History
INSP Split History
INSY Split History
INVA Split History
IPCI Split History
IRON Split History
IRWD Split History
ISRG Split History

Also explore: INFI shares outstanding history

Email EnvelopeFree INFI Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Liminal BioSciences Inc. (LMNL)
Galway Metals Inc. (GWM.CA)
Lannett Company, Inc. (LCI)
Reed's, Inc. (REED)
Phio Pharmaceuticals Corp. (PHIO)
Swvl Holdings Corp (SWVL)
Sientra, Inc. (SIEN)
Eargo, Inc. (EAR)
Alterity Therapeutics Limited (ATHE)
Aytu BioPharma, Inc. (AYTU)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

INFI Insider Buying

INFI Split History | www.SplitHistory.com | Copyright © 2013 - 2023, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.